LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

Search

Penumbra Inc

Atvērts

SektorsVeselības aprūpe

279.29 -1.21

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

277.74

Max

284.4

Galvenie mērījumi

By Trading Economics

Ienākumi

581K

46M

Pārdošana

15M

355M

P/E

Sektora vidējais

66.629

106.172

Peļņas marža

12.927

Darbinieki

4,500

EBITDA

4M

55M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+8.36% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.1B

11B

Iepriekšējā atvēršanas cena

280.5

Iepriekšējā slēgšanas cena

279.29

Ziņu noskaņojums

By Acuity

50%

50%

177 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Penumbra Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 19. nov. 23:36 UTC

Karstas akcijas

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

2025. g. 19. nov. 22:13 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Palo Alto Networks to Buy Chronosphere for $3.35 Billion, Posts Higher 1Q Revenue -- Update

2025. g. 19. nov. 21:55 UTC

Galvenie tirgus virzītāji

Amgen Lung Cancer Drug Gets Full Approval From FDA

2025. g. 19. nov. 21:43 UTC

Iegādes, apvienošanās, pārņemšana

Palo Alto Networks to Buy Chronosphere for $3.35 Billion

2025. g. 19. nov. 23:55 UTC

Tirgus saruna

Gold Rises on Possible Investment Demand -- Market Talk

2025. g. 19. nov. 23:54 UTC

Tirgus saruna

BHP Vicuna JV Offers Significant Copper Output, At a Cost -- Market Talk

2025. g. 19. nov. 23:47 UTC

Peļņas

Lenovo Group 2Q EPS $2.52 >0992.HK

2025. g. 19. nov. 23:46 UTC

Peļņas

Lenovo Group: Delivered Double-Digit Yr-on-Yr Rev Growth Across All Main Business Groups and Sales Geographies >0992.HK

2025. g. 19. nov. 23:45 UTC

Peļņas

Lenovo Group 2Q Rev $20.5B >0992.HK

2025. g. 19. nov. 23:42 UTC

Tirgus saruna

Nikkei May Rise After Nvidia's Strong Earnings Soothe Investors' Nerves -- Market Talk

2025. g. 19. nov. 23:42 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 19. nov. 23:41 UTC

Peļņas

Lenovo Group 2Q Adj Net $512.0M Vs. $409.0M >0992.HK

2025. g. 19. nov. 23:41 UTC

Peļņas

Lenovo Group 2Q Net $340.0M Vs. Net $359.0M >0992.HK

2025. g. 19. nov. 23:40 UTC

Peļņas

Lenovo Group 2Q Rev $20.45B Vs. $17.85B >0992.HK

2025. g. 19. nov. 22:55 UTC

Peļņas

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 4th Update

2025. g. 19. nov. 22:41 UTC

Peļņas

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 3rd Update

2025. g. 19. nov. 22:30 UTC

Iegādes, apvienošanās, pārņemšana

CICC Seeks Trading Halt in Hong Kong, Shanghai Stock Exchange

2025. g. 19. nov. 22:30 UTC

Peļņas

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 2nd Update

2025. g. 19. nov. 22:30 UTC

Iegādes, apvienošanās, pārņemšana

CICC Plans to Acquire Brokerage Firms via Share-Swap Agreement

2025. g. 19. nov. 22:27 UTC

Iegādes, apvienošanās, pārņemšana

China International Capital Plans to Acquire Brokerage Firms Cinda Securities, Dongxing Securities

2025. g. 19. nov. 22:08 UTC

Peļņas

ZTO Express (Cayman) 3Q Rev $1.67B >ZTO

2025. g. 19. nov. 22:00 UTC

Peļņas

Investors Cheer Blockbuster Nvidia Earnings -- WSJ

2025. g. 19. nov. 21:58 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Palo Alto Networks to Buy Chronosphere for $3.35B, Posts Higher 1Q Rev -- Update

2025. g. 19. nov. 21:52 UTC

Peļņas

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- Update

2025. g. 19. nov. 21:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 19. nov. 21:49 UTC

Tirgus saruna
Peļņas

Nvidia Quiets Investor Fears With Ballooning Demand -- Market Talk

2025. g. 19. nov. 21:38 UTC

Peļņas

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- WSJ

2025. g. 19. nov. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Palo Alto Networks to Buy Chronosphere for $3.35B

2025. g. 19. nov. 21:27 UTC

Iegādes, apvienošanās, pārņemšana

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

2025. g. 19. nov. 21:24 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Palo Alto Networks 1Q Next-Generation Security ARR $5.9 B >PANW

Salīdzinājums

Cenas izmaiņa

Penumbra Inc Prognoze

Cenas mērķis

By TipRanks

8.36% augšup

Prognoze 12 mēnešiem

Vidējais 306.82 USD  8.36%

Augstākais 355 USD

Zemākais 266 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Penumbra Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

13 ratings

10

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

288.28 / 292.9394Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bullish Evidence

Noskaņojums

By Acuity

177 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat